These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28366271)

  • 21. [Renaissance of immuno-oncology for urological tumors : Current status].
    Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
    Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in immuno-oncology and its application to urological cancers.
    Mataraza JM; Gotwals P
    BJU Int; 2016 Oct; 118(4):506-14. PubMed ID: 27123757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.
    Gallagher DJ; Al-Ahmadie H; Ostrovnaya I; Gerst SR; Regazzi A; Garcia-Grossman I; Riches J; Gounder SK; Flaherty AM; Trout A; Milowsky MI; Bajorin DF
    Eur Urol; 2011 Aug; 60(2):344-9. PubMed ID: 21645967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing management of upper tract urothelial carcinoma.
    Campbell MT; Shah AY; Matin SF; Siefker-Radtke AO
    Urol Oncol; 2017 Jul; 35(7):492-498. PubMed ID: 28579283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunooncology in Urologic Cancers: Current Status].
    Grimm MO
    Aktuelle Urol; 2016 Sep; 47(5):374-7. PubMed ID: 27680188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety of second-line treatment options for non-small cell lung cancer.
    Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
    Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.
    Bertz S; Wach S; Taubert H; Merten R; Krause FS; Schick S; Ott OJ; Weigert E; Dworak O; Rödel C; Fietkau R; Wullich B; Keck B; Hartmann A
    Virchows Arch; 2016 Sep; 469(3):339-44. PubMed ID: 27392930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway.
    MacLaine NJ; Wood MD; Holder JC; Rees RW; Southgate J
    Mol Cancer Res; 2008 Jan; 6(1):53-63. PubMed ID: 18234962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and emerging targeted therapies for metastatic breast cancer.
    Perez EA; Spano JP
    Cancer; 2012 Jun; 118(12):3014-25. PubMed ID: 22006669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update in systemic therapy of urologic malignancies.
    Mooney D; Paluri R; Mehta A; Goyal J; Sonpavde G
    Postgrad Med; 2014 Jan; 126(1):44-54. PubMed ID: 24393751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
    Pasini F; Fraccon AP; Modena Y; Bencivenga M; Giacopuzzi S; La Russa F; Gusella M; de Manzoni G
    Gastric Cancer; 2017 Jan; 20(1):31-42. PubMed ID: 27568322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
    Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
    Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Urothelial tumors in 2016: Are we at the dawn of a new diagnostic and therapeutic era?].
    Pfister C
    Ann Pathol; 2016 Dec; 36(6):369-370. PubMed ID: 27912839
    [No Abstract]   [Full Text] [Related]  

  • 35. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
    Taguchi S; Nakagawa T; Matsumoto A; Nagase Y; Kawai T; Tanaka Y; Yoshida K; Yamamoto S; Enomoto Y; Nose Y; Sato T; Ishikawa A; Uemura Y; Fujimura T; Fukuhara H; Kume H; Homma Y
    Int J Urol; 2015 Jul; 22(7):638-43. PubMed ID: 25903328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel agents for muscle-invasive and advanced urothelial cancer.
    Sonpavde G; Ross R; Powles T; Sweeney CJ; Hahn N; Hutson TE; Galsky MD; Lerner SP; Sternberg CN
    BJU Int; 2008 Apr; 101(8):937-43. PubMed ID: 18005203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular signaling and the role of targeted therapies in bladder cancer.
    Black PC
    Minerva Urol Nefrol; 2012 Mar; 64(1):7-17. PubMed ID: 22402314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Schistosomiasis and bladder cancer: similarities and differences from urothelial cancer.
    Zaghloul MS; Gouda I
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):753-63. PubMed ID: 22716492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging growth factor receptor antagonists for the treatment of advanced melanoma.
    Fenton SE; Sosman JA; Chandra S
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):165-174. PubMed ID: 28562096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.